Targeted effector Molecules

Our Approach

Morphimmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases efficacy of known effector molecules, ultimately improving outcomes for patients.

Morphimmune was founded on the research of the company’s Scientific Founder, Philip S. Low, PhD, the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low is the named inventor of more than 100 patents and the founder of seven companies to commercialize these discoveries. 


Targeted Immunotherapy
Folate Receptor-Targeted TLR7a

Toll-Like Receptor 7 (TLR7) is a promising oncology target that induces a robust immune response when activated. Morphimmune's folate receptor targeted TLR7 agonist (FA-TLR7a) takes a unique approach, delivering its potent, proprietary payload directly to immunosuppressive cells in the tumor microenvironment. The result is a drug with  monotherapy promise and the potential for synergistic combination therapy when combined with checkpoint inhibitors.

Targeted Radioligand
FAP Radiotherapy

Morphimmune is advancing a Fibroblast Activation Protein (FAP) targeted radioligand therapy with multi-indication potential. FAP is expressed in over 75% of solid tumors including lung, breast, and esophageal cancer. MorphImmune's preclinical candidates build on work Low Lab at Purdue, which also patented key components of Pluvicto™.

Targeted Effector Platform

toolbox approach
Modular Design 

MorphImmune’s modular, chemistry-driven approach enables rapid design, screening, and development of new molecules. Ligands, linkers, and effectors can be combined to pursue both novel and well-validate targets and to deliver known or novel effector payloads.  

Small Molecule Advantage

MorphImmune’s Targeted Effector platform uses ligands with antibody-like specificity to deliver potent effectors—an approach that has proven successful for antibody-drug conjugates. But MorphImmune’s platform also benefits from the best characteristics of small molecules:
Superior tissue penetration
Ability to access intracellular targets
• Tunable pharmacokinetics
Potential for oral dosing

Pinpoint Delivery

MorphImmune’s high-affinity small molecule ligands enable pinpoint payload delivery, reducing toxicity and improving therapeutic index. Despite recent advancements, significant unmet patient need remains in cancer, autoimmune disease, and inflammation. Toxicity causes serious burdens to patients and limits the use of otherwise efficacious drugs. MorphImmune’s high-affinity ligands selectively targets receptors that are overexpressed on disease-implicated cells. The result is pinpoint delivery of payloads, reducing toxicity and increasing therapeutic index. 

Read our latest press release

Read now